HIV-inhibiting benzeneacetamide derivatives

A method for treating human cells which comprises administering a pharmaceutically acceptable carrier and a compound of the formula:

• ##STR25## a pharmaceutically acceptable acid addition salt form or a stereochemically isomeric form thereof, wherein:
• R.sup.1 and R.sup.2 each independently are hydrogen, C.sub.1-6 alkyl or C.sub.3-6 cyclo-alkyl;
• or R.sup.1 and R.sup.2 taken together with the nitrogen atom bearing said R.sup.1 and R.sup.2 may form a pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl or 4-C.sub.1-4 alkylpiperazinyl group;
• X is O or S;
• R.sup.3 is hydrogen or C.sub.1-6 alkyl;
• R.sup.4, R.sup.5 and R.sup.6 each independently are hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, nitro, trifluoromethyl, cyano, aminomethyl, carboxyl;
• C.sub.1-4 alkyloxycarbonyl, C.sub.1-4 alkylcarbonyl, aminocarbonyl or hydroxy;
• R.sup.7 is hydrogen or halo;
• R.sup.8, R.sup.9 and R.sup.10 each independently are hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, nitro, hydroxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, (trifluoromethyl)carbonyl, aminocarbonyl, (cyclopropyl)-carbonyl or a radical of the formula C.sub.1-6 alkyl-(C.dbd.alkyl-(C.dbd.Y)- wherein .dbd.Y represents .dbd.O, .dbd.N--OCH.sub.3, .dbd.N--NH.sub.2, or .dbd.N--N(CH.sub.3).sub.2 ;
• provided that:
• (1) R.sup.1 is other than n-propyl when R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.9, and R.sup.10 represent hydrogen, R.sup.8 represents 4-ethoxy and x represents oxygen;
• and
• (2) X is other than sulfur when R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.9, and R.sup.10 represent hydrogen and R.sup.4 and R.sup.5 represent 3,4-dimethoxy,
• said compound being administered in an amount effective to inhibit the replication and effects of HIV-1 in human cells to which said compound is administered.